Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing, 3rd Edition

Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing, 3rd Edition
  • Report price : $ 3 500
  • Publication date : January 2009

Get this report now!

Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing, 3rd Edition

This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector.

A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the core competency of pharmaceutical and biotechnology drug makers.

Detail on Biopharmaceutical Markets

The growing number of biotechnology-driven protein and peptide drugs, antibiotics, chemotherapeutic agents and other compounds administered as sterile injectables, with its concomitant technological requirements, has brought about an increase in the demand for contract sterile manufacturing services. The sheer numbers of biologics in the pipeline are driving drug makers to outsource specialized production rather than build new plants.

As part of its unique coverage of the outsourcing markets for manufacturing and sales, this report includes



  • CMO and CSO Market Size and Forecasts

  • Regional Market Breakout (US, Europe, Japan, Latin America, Rest of World)

  • Overview of CMO/CSO Market and Key Drivers

  • Key Issues and Trends

  • Biopharmaceutical Manufacturing

  • Assessment of Key Companies in the Market
Traditionally, large pharmaceutical companies considered sales and marketing a core competency, and built in-house sales teams and the infrastructure to support promotional activities, launches and general portfolio expansion. However, in recent years, consistent with the ``lean-and-mean`` business model evolving in the pharmaceutical industry, sales and marketing is shifting—albeit slowly—from a core competency to a prime candidate for outsourcing.

Primary and Secondary Research



The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.  
 


RELATED REPORTS

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)

  • $ 3 500
  • January 2009

A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated ...

Industries : Pharmaceutical

Molecular Diagnostics: a primer on an emerging sector

Molecular Diagnostics: a primer on an emerging sector

  • $ 7 600
  • November 2008
  • 147 pages

IntroductionThis report analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests which are positioned in this exciting area of diagnostics. The current MDx market size and leading players are analyzed, with a market f ...

Industries : Pharmaceutical

Shire plc: PharmaVitae Profile

Shire plc: PharmaVitae Profile

  • $ 5 700
  • November 2008
  • 158 pages

IntroductionThis analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interac ...

Industries : Pharmaceutical

Pipeline and Commercial Insight: Anxiety Disorders - Viable indication for antipsychotics companies

Pipeline and Commercial Insight: Anxiety Disorders - Viable indication for antipsychotics companies

  • $ 15 200
  • November 2008
  • 257 pages

IntroductionDespite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and m ...

Industries : Pharmaceutical

Stakeholder Insight: Systemic Lupus Erythematosus  Imprecise segmentation complicates treatment algorithms

Stakeholder Insight: Systemic Lupus Erythematosus Imprecise segmentation complicates treatment algorithms

  • $ 15 200
  • November 2008
  • 179 pages

IntroductionDespite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and m ...

Industries : Pharmaceutical

The World Market for Gastrointestinal Endoscopy Equipment

The World Market for Gastrointestinal Endoscopy Equipment

  • $ 3 500
  • January 2009

The gastrointestinal endoscopy market is a market on the rise. With continually advancing technologies available and world population increasing every year, the gastrointestinal endoscopy market. Market Driven by Aging Population, Growth in GI Disease CasesGrowth in this market encompasses many area ...

Industries : Pharmaceutical

World Generics Market, 2008-2013

World Generics Market, 2008-2013

  • $ 2 501
  • November 2008

The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic p ...

Industries : Pharmaceutical

The Global Pain Market, 2008-2023

The Global Pain Market, 2008-2023

  • $ 2 501
  • November 2008

The global pain market generated total sales of $34bn in 2007 - but what will the figures be in the next 5 and 10 years? This report tells you. The pain market has marked strengths and advantages, but is also limited by problems and concerns. The market will be driven by new drugs and reformulations ...

Industries : Pharmaceutical

China Blood Products Industry Report, 2007-2008

China Blood Products Industry Report, 2007-2008

  • $ 950
  • December 2008
  • 30 pages

China blood products industry is all along comparatively independent from global blood products industry. In the year of 1986, according to the rules from Ministry of Health, China prohibited the import of blood products except HAS. However, since 2002, HAS import had been also prohibited from BSE d ...

Industries : Pharmaceutical | Countries : China

China Chemical Pharmaceutical Market Report, 2008

China Chemical Pharmaceutical Market Report, 2008

  • $ 1 700
  • December 2008
  • 81 pages

By the end of Aug, 2008, the total output value of China’s chemical pharmaceutical industry was CNY 273.272 billion, among which, the total output value of active pharmaceutical ingredient (API) was CNY 122.467 billion and the total output value of chemical reagent was CNY 150.805 billion.By the e ...

Industries : Pharmaceutical | Countries : China

reportlinker.com © Copyright 2009. All rights reserved

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.